Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation

NCT01094171 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01094171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01094171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
December 3, 2010
Completion date
October 27, 2012
Enrollment
400 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

poliomyelitis